|Dr. Vicente J. Anido Jr.||CEO & Chairman||1.16M||11.84M||1953|
|Mr. Thomas A. Mitro||Pres & COO||621k||10.85M||1958|
|Dr. Casey C. Kopczynski||Co-Founder & Chief Scientific Officer||578.03k||169.56k||1961|
|Mr. Richard James Rubino CPA||CFO, Sec. & Treasurer||631.12k||N/A||1958|
|Mr. John W. LaRocca Esq.||Gen. Counsel & Assistant Sec.||521.07k||N/A||1966|
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Aerie Pharmaceuticals, Inc.’s ISS governance QualityScore as of 4 December 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 8; Compensation: 7.